Home Featured Page 251

Featured

Latest

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

Op-ed: UK Public Support Psilocybin Research & Rescheduling Despite Government Stance

Mindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic...

Field Trip Health Ltd. to Commence Trading on the Toronto Stock...

MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use...

Silo Wellness Partners with Mushe Inc. to Establish First Legal Brick...

COMPASS Pathways and Kings College London publish cognition results from COMP360...

Psychedelics: A New Fountain of Youth?

MEC Announces Submission of Listing Statement to the CSE in Coordination...

The Psilocybin vs. Escitalopram Trial – Part 2

Psychedelics and Cannabis ETF Launches on NYSE Arca in First for...

1...250251252...306 Page 251 of 306

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

Op-ed: UK Public Support Psilocybin Research & Rescheduling Despite Government Stance

Mindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic...

Field Trip Health Ltd. to Commence Trading on the Toronto Stock...

MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use...

Silo Wellness Partners with Mushe Inc. to Establish First Legal Brick...

COMPASS Pathways and Kings College London publish cognition results from COMP360...

Psychedelics: A New Fountain of Youth?

MEC Announces Submission of Listing Statement to the CSE in Coordination...

The Psilocybin vs. Escitalopram Trial – Part 2

Psychedelics and Cannabis ETF Launches on NYSE Arca in First for...

EDITOR PICKS

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY